Synthesis and anticancer activity of 2,4-disubstituted furo[3,2-b] indole derivatives

European Journal of Medicinal Chemistry

Volumn 66, Issue , 2013, Pages 466-479

  Zhuang, Shi Hong ^a   Lin, Yi Chien ^a   Chou, Li Chen ^a   Hsu, Mei Hua ^a   Lin, Hui Yi ^a   Huang, Chi Hung ^b   Lien, Jin Cherng ^a   Kuo, Sheng Chu ^a   Huang, Li Jiau ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b Taiwan Advance Biopharm Inc   (Taiwan)

Author keywords

A498 renal cancer cells; Anticancer activity; Furo 3,2 b indole derivatives; Structure activity relationships (SARs)

Indexed keywords

2,4 DISUBSTITUTED FURO[3,2 B]INDOLE DERIVATIVE; 4 BENZYL 4H FURO[3,2 B]INDOLE 2 CARBOXYLIC ACID; 4 ETHYL 4H FURO[3,2 B]INDOLE 2 CARBOXYLIC ACID; 4 METHYL 4H FURO[3,2 B]INDOLE 2 CARBOXYLIC ACID; 4 METHYL 4H FURO[3,2 B]INDOLE 2 METHANOL; 4H FURO[3,2 B]INDOLE 2 CARBOXYLIC ACID; 4H FURO[3,2 B]INDOLE 2 METHANOL; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; LIFICIGUAT; METHYL 4 (2 CHLOROBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (2 FLUOROBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (2 METHOXYBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (3 CHLOROBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (3 FLUOROBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (3 METHOXYBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (4 CHLOROBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (4 FLUOROBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 (4 METHOXYBENZYL) 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 BENZYL 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 ETHYL 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 METHYL 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 [3 (METHOXYCARBONYL)BENZYL] 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 [3,4 (METHYLENEDIOXY)BENZYL] 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 [4 (METHOXYCARBONYL)BENZYL] 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 [[5 (METHOXYCARBONYL)FURAN 2 YL]METHYL] 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 [[5 (METHOXYCARBONYL)SELENOPHEN 2 YL]METHYL] 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; METHYL 4 [[5 (METHOXYCARBONYL)THIOPHEN 2 YL]METHYL] 4H FURO[3,2 B]INDOLE 2 CARBOXYLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [5 [[2 (HYDROXYMETHYL) 4H FURO[3,2 B]INDOL 4 YL]METHYL]FURAN 2 YL]METHANOL; 4 BENZYL 4H FURO[3,2 B]INDOLE 2 METHANOL; 4 ETHYL 4H FURO[3,2 B]INDOLE 2 METHANOL; [5 [(2 (HYDROXYMETHYL) 4H FURO[3,2 B]INDOL 4 YL]METHYL] FURAN 2 YL] METHANOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY CANCER; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OVARY CANCER; SCREENING TEST; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; CANCER CELL LINE; CANCER GROWTH; CANCER SIZE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; G2 PHASE CELL CYCLE CHECKPOINT; HL 60 CELL LINE; IC50; MALE; MASS SPECTROMETRY; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RENAL CANCER CELL LINE; WESTERN BLOTTING;

EID: 84879810917     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.06.012     Document Type: Article

References (29)

1. H.K. Hsu, S.H. Juan, P.Y. Ho, Y.C. Liang, C.H. Lin, C.M. Teng, W.S. Lee, YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway, Biochem. Pharmacol. 66 (2003) 263-271.
2. S.L. Pan, J.H. Guh, C.Y. Peng, S.W. Wang, Y.L. Chang, F.C. Cheng, J.H. Chang, S.C. Kuo, F.Y. Lee, C.M. Teng, YC-1 [3-(5′-Hydroxymethyl-2′- furyl) -1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models, J. Pharmacol. Exp. Ther. 314 (2005) 35-42.
3. S.L. Pan, J.H. Guh, C.Y. Peng, Y.L. Chang, F.C. Cheng, J.H. Chang, S.C. Kuo, F.Y. Lee, C.M. Teng, A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models, Thromb. Haemost. 93 (2005) 940-948.
4. S.W. Wang, S.L. Pan, J.H. Guh, H.L. Chen, D.M. Huang, Y.L. Chang, S.C. Kuo, F.Y. Lee, C.M. Teng, YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1- benzyl indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells, J. Pharmacol. Exp. Ther. 312 (2005) 917-925.
5. Y.T. Huang, S.L. Pan, J.H. Guh, Y.L. Chang, F.Y. Lee, S.C. Kuo, C.M. Teng, YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells, Mol. Cancer Ther. 4 (2005) 1628-1635.
6. Y.N. Liu, S.L. Pan, C.Y. Peng, J.H. Guh, D.M. Huang, Y.L. Chang, C.H. Lin, H.C. Pai, S.C. Kuo, F.Y. Lee, C.M. Teng, YC-1 [3-(5′-Hydroxymethyl- 2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9, J. Pharmacol. Exp. Ther. 316 (2006) 35-41.
7. S.Y. Wu, S.L. Pan, T.H. Chen, C.H. Liao, D.Y. Huang, J.H. Guh, Y.L. Chang, S.C. Kuo, F.Y. Lee, C.M. Teng, YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway, Br. J. Pharmacol. 155 (2008) 505-513.
8. Y. Cheng, W. Li, Y. Liu, H.C. Cheng, J. Ma, L. Qiu, YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition, Chin. J. Cancer 31 (2012) 248-256.
9. L.C. Chou, L.J. Huang, J.S. Yang, F.Y. Lee, C.M. Tengc, S.C. Kuo, Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl) indazole (YC-1) as novel anti-leukemia agents, Bioorg. Med. Chem. 15 (2007) 1732-1740.
10. S.C. Kuo, F.Y. Lee, C.M. Teng, 1-(Substituted benzyl)-3-(substituted aryl)-condensed pyrazole derivatives and processed of making the same, U.S. Patent 5574168, 1996.
11. L.C. Chou, L.J. Huang, M.H. Hsu, M.C. Fang, J.S. Yang, S.H. Zhuang, H.Y. Lin, F.Y. Lee, C.M. Teng, S.C. Kuo, Synthesis of 1-benzyl-3-(5-hydroxymethyl-2- furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents, Eur. J. Med. Chem. 45 (2010) 1395-1402.
12. Y. Nakashima, Y. Kawashima, F. Amanuma, K. Sota, A. Tanaka, T. Kameyama, Furo [3, 2-b] indole derivatives. I. Synthesis and analgesic and anti-in flammatory activities of 4, 6-disubstituted-furo [3,2-b] indole-2-carboxamide derivatives, Chem. Pharm. Bull. 32 (1984) 4271-4280.
13. S. Tsuboi, S. Minura, S.I. Ono, K. Watanabe, A. Takeda, Oxidation of 2,4-alkadienoic esters with selenium dioxide. A new synthesis of furan and selenophenes, Bull. Chem. Soc. Jpn. 60 (1987) 1807-1812.
14. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines, J. Natl. Cancer Inst. 83 (1991) 757-766.
15. C.J. Chen, M.H. Hsu, L.J. Huang, T. Yamori, J.G. Chung, F.Y. Lee, C.M. Teng, S.C. Kuo, Anticancer mechanisms of YC-1 in human lung cancer cell line, NCIH226, Biochem. Pharmacol. 75 (2008) 360-368. (Pubitemid 350298460)
16. M.V. Berridge, A.S. Tan, Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction, Arch. Biochem. Biophys. 303 (1993) 474-482. (Pubitemid 23199849)
17. P.E. Newburger, C. Speier, N. Borregaard, C.E. Walsh, J.C. Whitin, E.R. Simons, Development of the superoxide-generating system during differentiation of the HL-60 human promyelocytic leukemia cell line, J. Biol. Chem. 259 (1984) 3771-3776. (Pubitemid 14173417)
18. D.M. Euhus, C. Hudd, M.C. LaRegina, F.E. Johnson, Tumor measurement in the nude mouse, J. Surg. Oncol. 31 (1986) 229-234. (Pubitemid 16104025)
19. M.M. Tomayko, C.P. Reynolds, Determination of subcutaneous tumor size in athymic (nude) mice, Cancer Chemother. Pharmacol. 24 (1989) 148-154. (Pubitemid 19163397)
20. 6-methylguanine, Mutagenesis 17 (2002) 483-487.
21. S. Lakhanpal, R.C. Donehower, E.K. Rowinsky, Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma, Invest. New Drugs 19 (2001) 69-76. (Pubitemid 32209786)
22. M. Cuendet, K. Christov, D.D. Lantvit, Y. Deng, S. Hedayat, L. Helson, J.D. McChesney, J.M. Pezzuto, Multiple myeloma regression mediated by bruceantin, Clin. Cancer Res. 10 (2004) 1170-1179. (Pubitemid 38198919)
23. S.R. Patel, L.K. Kvols, J. Rubin, M.J. O'Connell, J.H. Edmonson, M.M. Ames, J.S. Kovach, Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma, Invest. New Drugs 9 (1991) 53-57.
24. G. Northrop, S.G. Taylor III, R.I. Northrop, Biochemical effects of mithramycin on cultured cells, Cancer Res. 29 (1969) 1916-1919.
25. C.R. Garrett, D. Coppola, R.M. Wenham, C.L. Cubitt, A.M. Neuger, T.J. Frost, R.M. Lush, D.M. Sullivan, J.Q. Cheng, S.M. Sebti, Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT, Invest. New Drugs 29 (2011) 1381-1389.
26. J. Westendorf, M. Aydin, G. Groth, O. Weller, H. Marquardt, Mechanistic aspects of DNA damage by morpholinyl and cyanomorpholinyl anthracyclines, Cancer Res. 49 (1989) 5262-5266. (Pubitemid 19240458)
27. J.L. Nitiss, P. Pourquier, Y. Pommier, Aclacinomycin A stabilizes topoisomerase I covalent complexes, Cancer Res. 57 (1997) 4564-4569. (Pubitemid 27441062)
28. H. Gao, E.F. Yamasaki, K.K. Chan, L.L. Shen, R.M. Snapka, Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIa/b poison, Cancer Res. 60 (2000) 5937-5940.
29. L.G. May, M.A. Madine, M.J. Waring, Echinomycin inhibits chromosomal DNA replication and embryonic development in vertebrates, Nucleic Acids Res. 32 (2004) 65-72. (Pubitemid 38228605)